A partially randomised trial of pretomanid, moxifloxacin and pyrazinamide for pulmonary TB
Conor Tweed(MRC Clinical Trials Unit at UCL), Stephen H. Gillespie(University of St Andrews), Timothy D. McHugh(University College London), Mookho Malahleha(University of Cape Town), Francis Mhimbira(Ifakara Health Institute), Angela M. Crook(MRC Clinical Trials Unit at UCL), Videlis Nduba(Kenya Medical Research Institute), Evans Amukoye(Kenyatta National Hospital), Melvin Spigelman(TB Alliance), C.H. van Niekerk(TB Alliance), Suzanne Staples, Müge Çevik(University of St Andrews), Raesibe AP Selepe(Aurum Institute), Susan Swindells(University of Nebraska Medical Center), Leandra Lombard(TB Alliance), Umesh Lalloo(Wentworth Hospital), William Brumskine(Aurum Institute), Andrew Nunn(University College London), Issa Sabi(National Institute for Medical Research), Carl M. Mendel(TB Alliance), Ahmad Izuanuddin Ismail(Universiti Teknologi MARA), Vincent M. Balanag(Lung Center of the Philippines), Richard E. Chaisson(Johns Hopkins University), Francesca Conradie(University of the Witwatersrand), Janice Caoili(Makati Medical Center), Ebrahim Variava(Kalafong Hospital), Ronelle Moodliar, Stella M. Fabiane(MRC Clinical Trials Unit at UCL), Robert Hunt(University College London), Anna L. C. Bateson(University College London), A Parigi(TB Alliance), Matt Betteridge(TB Alliance), Andreas H. Diacon(Stellenbosch University), Daniel E. Everitt(TB Alliance), C. Louw(University of Pretoria), Modulakgotla Sebe(Aurum Institute), Genevieve H. Wills(MRC Clinical Trials Unit at UCL), Rodney Dawson(University of Cape Town)
Cited by 63
Related Papers
Identification of a Reservoir for HIV-1 in Patients on Highly Active Antiretroviral Therapy
|Science|1997|3.1k
SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis
|The Lancet Microbe|2020|1.5k
Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis
|Clinical Infectious Diseases|2016|1.5k
Four-Month Moxifloxacin-Based Regimens for Drug-Sensitive Tuberculosis
|New England Journal of Medicine|2014|653